Literature DB >> 21989943

Molecular Imaging and Contrast Agent Database (MICAD): evolution and progress.

Arvind Chopra1, Liang Shan, W C Eckelman, Kam Leung, Martin Latterner, Stephen H Bryant, Anne Menkens.   

Abstract

The purpose of writing this review is to showcase the Molecular Imaging and Contrast Agent Database (MICAD; www.micad.nlm.nih.gov ) to students, researchers, and clinical investigators interested in the different aspects of molecular imaging. This database provides freely accessible, current, online scientific information regarding molecular imaging (MI) probes and contrast agents (CA) used for positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging, X-ray/computed tomography, optical imaging and ultrasound imaging. Detailed information on >1,000 agents in MICAD is provided in a chapter format and can be accessed through PubMed. Lists containing >4,250 unique MI probes and CAs published in peer-reviewed journals and agents approved by the United States Food and Drug Administration as well as a comma separated values file summarizing all chapters in the database can be downloaded from the MICAD homepage. Users can search for agents in MICAD on the basis of imaging modality, source of signal/contrast, agent or target category, pre-clinical or clinical studies, and text words. Chapters in MICAD describe the chemical characteristics (structures linked to PubChem), the in vitro and in vivo activities, and other relevant information regarding an imaging agent. All references in the chapters have links to PubMed. A Supplemental Information Section in each chapter is available to share unpublished information regarding an agent. A Guest Author Program is available to facilitate rapid expansion of the database. Members of the imaging community registered with MICAD periodically receive an e-mail announcement (eAnnouncement) that lists new chapters uploaded to the database. Users of MICAD are encouraged to provide feedback, comments, or suggestions for further improvement of the database by writing to the editors at micad@nlm.nih.gov.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21989943      PMCID: PMC3259264          DOI: 10.1007/s11307-011-0521-3

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  27 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 2.  Iodinated blood pool contrast media for preclinical X-ray imaging applications--a review.

Authors:  François Hallouard; Nicolas Anton; Philippe Choquet; André Constantinesco; Thierry Vandamme
Journal:  Biomaterials       Date:  2010-05-26       Impact factor: 12.479

Review 3.  Imaging Probe Development Center: a National Institutes of Health core synthesis resource for imaging probes.

Authors:  Zhen-Dan Shi; Haitao Wu; Brian Ruddy; Gary L Griffiths
Journal:  J Biomed Opt       Date:  2007 Sep-Oct       Impact factor: 3.170

Review 4.  Molecular and magnetic resonance imaging: The value of immunoliposomes.

Authors:  Dorota Kozlowska; Paul Foran; Peter MacMahon; Martin J Shelly; Stephen Eustace; Richard O'Kennedy
Journal:  Adv Drug Deliv Rev       Date:  2009-09-29       Impact factor: 15.470

Review 5.  Multimodality imaging probes: design and challenges.

Authors:  Angelique Louie
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 6.  Deorphanization of novel peptides and their receptors.

Authors:  Akihiko Ozawa; Iris Lindberg; Bryan Roth; Wesley K Kroeze
Journal:  AAPS J       Date:  2010-05-06       Impact factor: 4.009

Review 7.  An integrated approach for the rational design of nanovectors for biomedical imaging and therapy.

Authors:  Biana Godin; Wouter H P Driessen; Bettina Proneth; Sei-Young Lee; Srimeenakshi Srinivasan; Rolando Rumbaut; Wadih Arap; Renata Pasqualini; Mauro Ferrari; Paolo Decuzzi
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

8.  Estrogen receptor and breast MR imaging features: a correlation study.

Authors:  Jeon-Hor Chen; Hyeon-Man Baek; Orhan Nalcioglu; Min-Ying Su
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

9.  Determination of optimal rhodamine fluorophore for in vivo optical imaging.

Authors:  Michelle R Longmire; Mikako Ogawa; Yukihiro Hama; Nobuyuki Kosaka; Celeste A S Regino; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2008-07-09       Impact factor: 4.774

Review 10.  Toxicity of MRI and CT contrast agents.

Authors:  Kendra M Hasebroock; Natalie J Serkova
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

View more
  14 in total

Review 1.  Advancing biomedical imaging.

Authors:  Ralph Weissleder; Matthias Nahrendorf
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

2.  Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?

Authors:  Gang Cheng; Thomas J Werner; Andrew Newberg; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

Review 3.  New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.

Authors:  Graham Smith; Laurence Carroll; Eric O Aboagye
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

4.  Essential parameters to consider for the characterization of optical imaging probes.

Authors:  Kam Leung; Arvind Chopra; Liang Shan; William C Eckelman; Anne E Menkens
Journal:  Nanomedicine (Lond)       Date:  2012-07       Impact factor: 5.307

5.  A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.

Authors:  Zhen Ye; Zhuxian Zhou; Nadia Ayat; Xueming Wu; Erlei Jin; Xiaoyue Shi; Zheng-Rong Lu
Journal:  Contrast Media Mol Imaging       Date:  2015-07-27       Impact factor: 3.161

6.  Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.

Authors:  Maria Cekanova; Md Jashim Uddin; Alfred M Legendre; Gina Galyon; Joseph W Bartges; Amanda Callens; Tomas Martin-Jimenez; Lawrence J Marnett
Journal:  J Biomed Opt       Date:  2012-11       Impact factor: 3.170

Review 7.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

Review 8.  Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.

Authors:  Irina Velikyan
Journal:  Contrast Media Mol Imaging       Date:  2018-01-04       Impact factor: 3.161

Review 9.  Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome.

Authors:  Mark S Cooper; Vincent P Clark
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-25       Impact factor: 4.147

Review 10.  The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology.

Authors:  Mark P S Dunphy; Nagavarakishore Pillarsetty
Journal:  Cancers (Basel)       Date:  2020-09-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.